glp-1 obesity drug market forecast 2030 Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Report: Size, Growth, Trends & (2025–2033) Targeted_Treatments GLP-1 drugs and vision Quantity:Triple-Pack ($169)

glp-1 obesity drug market forecast 2030 Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Report: Size, Growth, Trends & (2025–2033) Targeted_Treatments GLP-1 drugs and vision Quantity:Triple-Pack ($169)

GLP-1 drugs and vision loss: How significant are the risks?

in Spain, its current prevalence ranges between 28–33%11,12 and it is a recognized as a cardiovascular risk factor and increases the mortality in this population.13–15 Furthermore, in patients with DM2 and advanced CKD there are limitations in the prescription of certain antihyperglycemic drugs (e.g., metformin or sulfonylureas) and there is an increased risk of hypoglycemia with antihyperglycemic treatment,16 a complication that is associated with increased cardiovascular risk17 and hinders the achievement of glycemic control targets

Targeted_Treatments

Quantity:Triple-Pack ($169)

The study was published on December 11, 2023, in JAMA Internal Medicine